

# Traditional and New Influenza Vaccines

Sook-San Wong, Richard J. Webby

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

<b>SUMMARY</b> .....	476
<b>INTRODUCTION</b> .....	476
Variability of Influenza Virus .....	477
Animal Reservoirs .....	477
Immunological Response to Influenza Virus Infection .....	477
<b>CONVENTIONAL APPROACHES TO INFLUENZA VACCINES</b> .....	478
Influenza Vaccination .....	478
Trivalent inactivated vaccine .....	478
Live attenuated influenza virus .....	479
Vaccine Strain Selection .....	479
Timeline Challenges in Conventional Vaccine Manufacturing .....	481
Achilles' Heels of the Current Influenza Vaccines .....	481
<b>VARIATION ON THE CONVENTIONAL</b> .....	482
Egg versus Cell Culture .....	482
Reverse Genetics .....	482
Role of Adjuvants .....	483
Route of Vaccine Delivery .....	483
High Dose of Hemagglutinin .....	483
<b>SAME TARGET, DIFFERENT APPROACH</b> .....	483
Baculovirus Expression Systems .....	484
Virus-Like Particles .....	484
Virus Vector Approaches .....	484
DNA Vaccines .....	484
<b>DIFFERENT TARGET, DIFFERENT APPROACH</b> .....	485
M2e-Based Vaccines .....	485
Cytotoxic T-Lymphocyte-Inducing Vaccines .....	485
Cross-Reactive HA Stalk Antibodies .....	486
<b>PERSPECTIVES</b> .....	487
<b>ACKNOWLEDGMENTS</b> .....	487
<b>REFERENCES</b> .....	487
<b>AUTHOR BIOS</b> .....	492

## SUMMARY

The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutinin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused primarily on improving production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe and scalable production, while adjuvants, dose variation, and alternate routes of delivery aim to improve vaccine immunogenicity. Fundamentally different approaches that are currently under development hope to signal new generations of influenza vaccines. Such approaches target nonvariable regions of antigenic proteins, with the idea of stimulating cross-protective antibodies and thus creating a “universal” influenza vaccine. While such approaches have obvious benefits, there are many hurdles yet to clear. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated based on the same antigenic target and newer technologies based on different antigenic targets.

## INTRODUCTION

Influenza virus is a successful human pathogen: its persistence in the human population and ability to cause sporadic pandemics make it a continuous public health threat. Seasonal influenza causes approximately 500,000 deaths worldwide and an estimated 16.7 deaths per 100,000 persons in the United States (1, 2). The burden of disease is especially high in populations with less robust immunity, such as children, the elderly, and chronically ill patients (2). It was estimated that in 2008, seasonal influenza viruses caused 90 million new infections worldwide in children younger than 5 years of age and were responsible for up to 20% of all pediatric acute lower respiratory infections (3). In the elderly, an aging immune system is thought to impair the ability to control infections, leading to increased morbidity and mortality (reviewed in reference 4). However, the impact of the disease on other age groups can be significantly greater during a pandemic.

Address correspondence to Richard J. Webby, Richard.Webby@stjude.org.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/CMR.00097-12

The 1918 Spanish flu pandemic was the most catastrophic, causing more than 50 million deaths worldwide, with a case fatality rate of 2.5% (5). The 2009 H1N1 pandemic virus was estimated to have caused more than 200,000 deaths during the first 12 months of its circulation (6). In addition, outbreaks of the highly pathogenic H5N1 avian influenza virus strains (with a case fatality rate of over 50% in zoonotic infections) are continuing throughout Asia and Africa, maintaining the global threat of influenza (7).

The three major genera of influenza virus, types A, B, and C, are all capable of causing human infections. Influenza A viruses are found in animal and human populations, whereas humans are considered the reservoir hosts of influenza B and C viruses. Types A and B are largely responsible for the annual incidences of human disease, whereas influenza C viruses cause sporadic, mild upper respiratory infections in children (8). Human seasonal influenza is typically mild, manifesting as fever, myalgia, and respiratory symptoms such as cough, sore throat, and rhinitis. More severe symptoms may include lower respiratory tract indications such as bronchitis and pneumonia, and patients may have an increased risk of secondary bacterial infections. Severe influenza infection can also lead to cardiovascular complications (reviewed in reference 9). Ninety percent of influenza-related deaths have been attributed to individuals older than 65 years of age (2).

Highly pathogenic strains of influenza virus, such as some of the avian H5 subtypes, on the other hand, can cause severe respiratory distress and multiorgan failure in infected humans (10). Atypical presentations of influenza can include gastrointestinal and neurological symptoms, both of which were observed frequently in individuals infected with the 2009 pandemic H1N1 strain (11, 12). Given their disease-causing potential, vaccination against influenza A and B viruses is a high public health priority.

### Variability of Influenza Virus

The influenza A and B virus genome is composed of eight negative-sense RNA segments. The virus particle consists of a host-derived lipid envelope embedded with 3 or 4 glycoproteins surrounding the ribonucleoprotein complex (RNP) and the polymerase (Pol) proteins (PB1, PB2, and PA). The major influenza virus surface glycoproteins are hemagglutinin (HA), neuraminidase (NA), and, in smaller proportions, matrix protein 2 (M2). Influenza B virus has an additional NB (neuraminidase gene region B) protein. Matrix protein 1 (M1) and nucleoprotein (NP) are associated with viral RNA and are important for viral assembly as well as budding, while the polymerase proteins are important for viral genome replication (13). HA and NA are the major antigenic proteins and are used to further classify influenza A viruses into multiple subtypes. Sixteen HA (H1 to H16) and 9 NA (N1 to N9) influenza A virus subtypes that are antigenically distinct have been identified, with the possible addition of a new subtype, H17, identified recently (13, 14). Currently, lineages of H1 and H3 viruses circulate endemically in humans. Only a single subtype of influenza B virus has been identified, although two distinct antigenic lineages (named B/Victoria and B/Yamagata) have evolved over time and cocirculate at variable levels in humans.

Influenza viruses have two major mechanisms of antigenic evolution: antigenic drift and antigenic shift. Antigenic drift occurs when the virus accumulates mutations at antigenic sites during replication through the actions of the inherently error-prone RNA polymerase, producing variant viruses that can escape existing

immunity. This phenomenon is common to both influenza A and B viruses. More dramatically, antigenic shift occurs when a virus acquires an antigenically novel HA through reassortment, a property made possible due to the segmented nature of the viral genome. Although both influenza A and B viruses undergo reassortment, antigenic shift is a feature of influenza A viruses only, due to the animal sources of antigenically distinct HA genes.

### Animal Reservoirs

Of the influenza viruses, only influenza A viruses have animal reservoirs. The natural reservoirs of influenza A viruses are wild aquatic birds, but a wide range of animal hosts can be infected. Apart from the recognized reservoir animal hosts (avian, swine, and equine), influenza viruses have also been isolated from cats, dogs, seals, and cheetahs, and most recently, viral RNA from a potentially novel H17 virus was detected in bats (13, 14). As infection can occur in a wide range of animal hosts, the potential for viral spread and reassortment in new hosts is high, necessitating active and constant surveillance to monitor the presence and spread of the virus. Furthermore, some of these animals, for example, the avian and swine hosts, have significant interactions at the animal-human interface, increasing the risk of zoonotic transmission and the possibility of subsequent human-to-human spread and pandemic emergence. Direct transmission of avian- or swine-origin influenza viruses can have grave implications; human infections by the highly pathogenic avian H5N1 subtype result from direct exposure to infected birds. While evidence of human-to-human transmission of the H5 virus is limited (15, 16), the threat of the strain acquiring airborne transmissibility in a mammalian host is real (17, 18). In addition, all human pandemics in the last century have occurred due to the introduction of either avian or swine influenza viruses or virus genes (19) into the human population.

### Immunological Response to Influenza Virus Infection

A challenge to the development of an effective immune response to influenza virus is the acute nature of the infection. Meta-analyses of human challenge studies with seasonal influenza viruses have shown that typical clinical symptoms peak on day 2 postinfection and resolve within 10 days, while viral shedding lasts an average of 4.8 days (20). The short infection period means that the local innate immune response is critical for restricting and clearing the infection. In humans, innate immunity to influenza virus is mediated by several mechanisms. Within infected cells, the viral RNA is recognized by pathogen recognition receptors (PRRs) such as the Toll-like receptors (TLRs) (TLR-3 and TLR-7), retinoic acid-inducible gene 1 (RIG-1), and nucleotide-binding oligomerization domain (NOD)-like receptor (NLR). Activation of these immune pathways leads to induction of interferon-mediated antiviral responses and secretion of proinflammatory cytokines, which helps to restrict virus replication. In addition, alveolar macrophages and natural killer (NK) cells and dendritic cells (DCs) all play a role by clearing virus-infected cells through phagocytosis and induction of apoptosis (reviewed in references 21 and 22).

The cellular arm of the adaptive immune response, mediated by CD4<sup>+</sup> T lymphocytes and CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs), has been shown in murine models to aid in virus clearance, suggesting that the same mechanism is probably important in human infections, although proof for the latter is still accumulating (23).

The CD8<sup>+</sup> CTLs recognize a broad range of influenza virus antigens, including the more conserved internal viral proteins that are presented in the context of HLA class molecules (24, 25). The ability of the cellular immune response to recognize conserved influenza virus proteins means that it is able to mount a cross-reactive response to various influenza virus strains (26–28). Conversely, the humoral arm of the immune response mediates its effector functions primarily by generating antibodies that target the virion surface-exposed viral proteins HA, NA, and, to a lesser extent, M2 (which is less abundant on the viral surface). HA, the major antigenic protein of influenza virus, functions as the viral attachment and membrane fusion protein. Thus, antibodies that target HA can neutralize the virus and prevent infection. The functional HA unit is a homotrimer, with each monomer comprised of 2 domains, HA1 and HA2, linked by a disulfide bond. HA2 forms the membrane anchor and the long alpha-helix “stem,” and HA1 forms the distal globular head that contains the receptor-binding sites and the majority of the antigenic sites. As discussed above, antigenic drifts in circulating strains are caused by changes to the antigenic sites in the HA1 globular head. It was predicted that the human seasonal H3 and H1 viruses have undergone between 2.1% and 3% amino acid changes per drift variant from 1999 to 2010. In contrast, the HA2 region is remarkably conserved, with only 3 amino acid changes noted for both H1 and H3 in the same time period (29). More importantly, HA2 is also immunogenic. Antibodies that target this region have been found in humans after infection and vaccination although at markedly reduced levels compared to those targeting the globular head (30, 31).

Influenza virus NA, the second major surface glycoprotein, is an enzyme that cleaves sialic acid residues on the cell surface to facilitate virus release. Antibodies to NA therefore do not prevent virus infection but instead will limit virus spread. Similarly, M2 and NP are both viral proteins that are important during the virus replication cycle. Antibodies that target these two proteins will not neutralize the virus but have been shown to restrict virus replication in mice (32).

Induction of HA-specific serum antibodies, as typically measured by a hemagglutination inhibition or neutralization assay, is used as an indicator of recent exposure or vaccination. Based on reported vaccine and clinical studies, a titer of  $\geq 40$  may be considered to be an immune correlate for protection for inactivated influenza vaccines in adults. Immune correlates of protection for other vaccine platforms are, however, lacking. This has been identified as an important aspect hampering the development of novel influenza vaccination approaches (33). Direct measurement of vaccine protective efficacy, which refers to the ability of the vaccine to prevent infection in a field setting, is difficult to assess empirically, as, among many obstacles, it requires a large study cohort and the ability to monitor the participants over at least one influenza season (34). With these points in mind, development of a clinically proven influenza vaccine is a lengthy and costly endeavor.

## CONVENTIONAL APPROACHES TO INFLUENZA VACCINES

### Influenza Vaccination

In humans, the seasonal influenza vaccine is supposed to protect against endemic H1N1, H3N2, and B strains that circulate in humans globally. While efforts have been made to prepare stockpile

vaccine against zoonotic animal strains, the following descriptions relate primarily to seasonal human vaccines, unless otherwise stated. The goals of influenza vaccination can be broadly defined on 2 levels: (i) protection against infection and disease and (ii) induction of herd immunity to restrict virus transmission within the population (35). Major events in the development of influenza vaccines are presented in Fig. 1. Although early vaccine studies in the 1930s and 1940s that used crude preparations of live and inactivated influenza A virus were not consistently successful in reducing the incidence of febrile illnesses, they did demonstrate the importance of antigen potency and matching vaccine strains (36). Subsequent multicenter studies commissioned by the U.S. Armed Forces Epidemiological Board used inactivated, concentrated virus stocks incorporating multiple virus strains and found prophylactic protection and a much lower incidence of febrile illnesses in vaccinated groups than in controls, laying the foundations for influenza vaccination programs (37). Current recommendations for influenza vaccination vary among countries. In the United States, annual influenza vaccination has been recommended for high-risk groups since the 1960s, but it was only in 2010 that the Advisory Committee on Immunization Practices (ACIP) made the first recommendation for a national influenza vaccination to include individuals aged 6 months to 18 years (38). In Europe, most countries still generally recommend vaccination only for the elderly, the chronically ill, and residents of health care facilities (39). Because influenza vaccines do not induce long-lasting antibody titers, annual influenza vaccination is recommended prior to the start of the winter seasons, a fact that in itself poses difficulties for tropical countries, where the peak influenza seasons are less well delineated (40, 41).

**Trivalent inactivated vaccine.** The most widely used seasonal influenza vaccine is the trivalent inactivated vaccine (TIV). The conventional vaccine is composed of the 3 currently circulating seasonal influenza virus strains: two influenza A virus types (H3N2 and H1N1) and a B type. The vaccines come in three major formulations: inactivated whole-virus, “detergent”-split, or subunit vaccines. Traditional licensed influenza vaccines are prepared from embryonated chicken eggs, inoculated individually with each virus type. Whole-virus vaccines are prepared from harvested allantoic fluid, chemically inactivated with formalin or  $\beta$ -propiolactone, and subsequently concentrated and purified to remove nonviral protein contaminants. The split-virus vaccine has an additional treatment step with detergent to dissociate the viral lipid envelope, exposing all viral proteins and subviral elements (42, 43). In subunit vaccines, the HA protein is further enriched through additional purification steps (44–46). Because the split-virus and subunit vaccines had comparable immunogenicity in primed populations but reduced reactogenicity compared to the whole-virus vaccine preparations, most contemporary vaccines since the 1970s have been split-virus or subunit formulations. In unprimed populations, such as young children, split-virus and subunit vaccines are less immunogenic, and two doses are required to achieve the 1:40 titer (47–49). TIVs provide immunity primarily by inducing antibodies that target the protective epitopes on HA. Some formulations may also induce NA-specific antibodies that do not protect from infection but may modulate the resulting disease.

A standard dose of TIV contains 15  $\mu$ g of HA per strain (total HA concentration of 45  $\mu$ g) and is administered as a single dose to those aged  $>9$  years. Younger children (between 6 months and 8 years of




FIG 1 Timeline of major events in influenza vaccine development. Influenza pandemics and major H5N1 outbreaks are indicated in red, while major breakthroughs in influenza vaccine development are highlighted in blue. Superscript numbers indicate references. \*, see the FDA website (<http://www.fda.gov/>); ^, see the European Medicines Agency website (<http://www.ema.europa.eu/>); #, see the CDC website (<http://www.cdc.gov/vaccines/acip/index.html>).

age) require two doses administered 4 weeks apart, if they have not been vaccinated in previous influenza seasons (for complete recommendations, see Table 1 and reference 38). The standard TIV is typically delivered as an intramuscular (i.m.) injection (although intradermal [i.d.] formulations are also available) and remains the most popular vaccine, primarily because of its widespread availability and relatively low cost. Recently, the U.S. Food and Drug Administration (FDA) has approved the quadrivalent version of Fluarix, a split-virion vaccine manufactured by GlaxoSmithKline Biologics that includes an additional type B strain to represent both antigenic lineages. By including an additional type B strain, it has been argued that the chance for a vaccine mismatch is reduced (50, 51). The quadrivalent inactivated vaccine (QIV) formulations appear to have immunogenicity and a safety profile comparable to those of the standard TIV (52; <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf>).

**Live attenuated influenza virus.** The rationale for developing the live attenuated influenza vaccine (LAIV) was to create a vaccine that mimics natural infection and, in doing so, theoretically induces both cellular and humoral immunity. Attenuated influenza viruses were first developed in the 1960s by serial passage of the virus in eggs under suboptimal conditions (53). The resulting attenuated viruses had temperature-sensitive phenotypes. These viruses were adapted to grow at 25°C (cold adapted [ca]), which is the normal temperature of the nasal passage, but not at temperatures higher than 35°C (temperature sensitive [ts]), which is the temperature of the respiratory tract. Because this restricts virus replication to the nasal passage, LAIV was expected to stimulate local humoral and cell-mediated immunity. These attenuated viruses were stable, immunogenic, and nontransmissible and were thus subsequently developed into "master donor" strains (54).

Master donor strains contribute their internal genes (all genes except the HA and NA genes) to generate vaccine strains with the desired HA and NA of the circulating strains. This is done either by classical reassortment in eggs or, when the technology became available, by reverse genetics. Since then, however, other strategies to generate attenuated viruses have been developed, mostly through molecular manipulations of internal genes. Several mutations in the PB2 and NS1 genes, for example, could also attenuate the virus and confer the temperature sensitivity phenotype to the virus (55–58). In contrast to TIV, LAIV is delivered intranasally (i.n.), induces a longer-lasting antibody titer, and is efficacious in children 2 to 7 years old (59, 60). However, because of the inherent risk of immunizing with live viruses, the LAIV is not recommended for immunocompromised individuals or individuals in close contact with these vulnerable populations. This vaccine platform may also have its drawbacks for development of vaccines against avian zoonotic strains, since they typically do not replicate in the human upper respiratory tract (61, 62), leading to disappointing results in some early clinical trials (63). A commercial LAIV produced by MedImmune was approved in 2003 by the FDA under the trade name FluMist. As of 2012, the FDA also approved the use of the quadrivalent formulation of FluMist, which includes an additional strain of the circulating influenza virus B type. LAIVs have been developed and used in Russia since the 1980s (64, 65).

### Vaccine Strain Selection

For conventional influenza vaccines to be maximally effective, the vaccine viruses have to be antigenically matched to the influenza viruses circulating in humans. The most appropriate vaccine strains are identified via an extensive and complex global surveil-



TABLE 1 Summary of FDA-approved seasonal influenza vaccines as of 2013<sup>a</sup>

Vaccine (yr licensed)	Manufacturer	Composition(s), delivery method	HA dose	Production source	Age(s) of target population(s)	Dose
Afluria (2007)	CSL, Australia	Trivalent, split virion, intramuscular	45 µg (15 µg HA/strain)	Egg	5–8 yr (unprimed) 5–8 yr (primed), ≥9 yr	Two 0.5-ml doses, 4 wk apart 0.5-ml single dose
FluLaval (2006)	ID Biomedical Corporation, Quebec, Canada	Trivalent, split virion, intramuscular	45 µg (15 µg HA/strain)	Egg	≥18 yr	0.5-ml single dose
Fluarix (2012)	GlaxoSmithKline Biologics	Quadrivalent, split virion, intramuscular	60 µg (15 µg HA/strain)	Egg	3–8 yr (unprimed) 3–8 yr (primed), ≥9 yr	Two 0.5-ml doses, 4 wk apart 0.5 ml single dose
Fluvirin (1998)	Novartis Vaccines and Diagnostics, Inc.	Trivalent, subunit, intramuscular	45 µg (15 µg HA/strain)	Egg	4–8 yr (unprimed) 4–8 yr (primed), ≥9 yr	Two 0.5-ml doses, 4 wk apart 0.5-ml single dose
Agriflu (2009)	Novartis Vaccines and Diagnostics, Inc.	Trivalent, subunit, intramuscular	45 µg (15 µg HA/strain)	Egg	≥18 yr	0.5-ml single dose
Flucelvax (2012)	Novartis Vaccines and Diagnostics, Inc.	Trivalent, subunit, intramuscular	45 µg (15 µg HA/strain)	MDCK cell derived	≥18 yr	0.5-ml single dose
Fluzone (1980)	Sanofi Pasteur, Inc.	Trivalent, split virion, intramuscular	45 µg (15 µg HA/strain)	Egg	6 mo–3 yr (unprimed) 6 mo–3 yr (primed) 3–8 yr (unprimed) 3–8 yr (primed), ≥9 yr	Two 0.25-ml doses, 4 wk apart 0.25-ml single dose Two 0.5-ml doses, 4 wk apart 0.5-ml single dose
Fluzone High-Dose (2009)	Sanofi Pasteur, Inc.	Trivalent, split virion, intramuscular	180 µg (60 µg HA/strain)	Egg	≥65 yr	0.5-ml single dose
Fluzone-Intradermal (2011)	Sanofi Pasteur, Inc.	Trivalent, split virion, intradermal	27 µg (9 µg HA/strain)	Egg	18–64 yr	0.1-ml single dose
FluBlok (2013)	Protein Sciences	Trivalent, intramuscular	135 µg each	ExpressSF+ (proprietary insect cells) using baculovirus expression system	18–49 yr	0.5-ml single dose
FluMist (2003)	MedImmune	Live attenuated, trivalent, intranasal	10 <sup>6.5</sup> –10 <sup>7.5</sup> FFU <sup>b</sup> virus/strain	Egg	2–8 yr (unprimed) 2–8 yr (primed) 9–49 yr	Two 0.2-ml doses, 4 wk apart 0.2-ml single dose
FluMist Quadrivalent (2012)	MedImmune	Live attenuated, quadrivalent, intranasal	10 <sup>6.5</sup> –10 <sup>7.5</sup> FFU virus/strain	Egg	2–8 yr (unprimed) 2–8 yr (primed), 9–49 yr	Two 0.2-ml doses, 4 wk apart 0.2-ml single dose

<sup>a</sup> Information was compiled from the FDA website (<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094045.htm>).<sup>b</sup> FFU, fluorescent focus units.

lance effort, coordinated by the World Health Organization (WHO) through its Global Influenza Surveillance and Response System (GISRS) network. The network comprises 6 collaborating centers (CCs), 4 essential regulatory laboratories, and 137 WHO-recognized national influenza centers (NICs) in 107 of its member states. More than 500,000 virological samples are screened at these NICs every year, of which approximately 8,000 are then sent to regional CCs for detailed genetic and antigenic analysis (66). Three types of data are generated and subsequently used to assess the relationship of circulating strains to the vaccine components and hence inform vaccine strain selection. The data types are antigenic data collected primarily through hemagglutinin inhibition assays using postinfection ferret antisera, and human serologic analyses using pre- and postvaccination serum samples and also viral HA sequence data. These data are presented during strain selection meetings held twice a year before the start of the winter seasons for the northern (February) and southern (September) hemispheres and form the basis for the annual recommendation for vaccine strains. It is worth noting that these recommendations are essentially made at least 6 months prior to the season in which the corresponding vaccine formulations will be used. Since 2004, the system has also provided additional guidance on representative zoonotic viruses for those countries and other entities interested in producing vaccine for clinical trials and/or national stockpiles.

### Timeline Challenges in Conventional Vaccine Manufacturing

The influenza vaccine pipeline faces a continual battle between the desire to delay vaccine strain selection to gather data on the most recently circulating viruses and the desire to make the selection earlier to allow for potential delays in vaccine manufacture. It is this battle of competing elements that is perhaps the single greatest challenge to the production of current influenza vaccines. The actual decision of vaccine strains to be used in a specific country is decided by national regulatory bodies, although these decisions typically mirror those recommended by the WHO. Selection of the appropriate strains begins the manufacturing stage of the influenza vaccine pipeline. The influenza A viruses that are used in vaccine manufacture are not the wild-type viruses themselves but rather high-growth reassortants that are hybrid viruses containing at least the HA and NA gene segments from the target strains and other gene segments from the master strain A/Puerto Rico/8/1934 (PR8), which has properties of high growth in eggs and also a favorable safety profile. Reassortant viruses are made by coinfection of eggs with PR8 and target strains, followed by selection of appropriate seed viruses by amplification in the presence of antibodies against the HA and NA of PR8. The resulting viruses are cloned and then sequenced for confirmation. The influenza B vaccine viruses are typically wild-type viruses, although type B reassortants have been utilized more recently when viral growth properties of the wild-type viruses have been suboptimal. In practice, the availability of high-growth influenza A virus reassortants is factored into WHO vaccine strain recommendations, as the process of their production can take weeks, and not all viruses generate reassortants with desirable growth and antigenic properties. Selection of a vaccine virus with poor growth properties would have major implications for the prompt delivery of vaccine, as the multivalent nature of the vaccine means that the worst-growing strain dictates the production time frame. Once appropriate high-growth reassortants are available, vaccine manufacturers then operate in a strict timeline to produce the

vaccine before the start of the influenza seasons. As discussed above, the time from strain selection to distribution is at least 6 months in an ideal setting ([http://www.who.int/csr/disease/swineflu/notes/h1n1\\_vaccine\\_20090806/en/index.html](http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/index.html)). However, the manufacturing process is susceptible to potential setbacks and requirements, such as a continuous egg supply, growth of virus, and meeting of regulatory requirements (67). Furthermore, manufacturers have to ensure strict conditions of biosafety and sterility. Because of these tight timelines, some manufacturers opt to start making vaccine from at least one of the three components “at risk” before the official strain decisions are made in order to allow for unexpected setbacks in production. These decisions are based on summaries from the WHO about influenza activity leading up to the vaccine composition meetings. Another time-critical step in this process is the development of potency reagents that are used to assess the amount of antigen in the final bulk vaccine. This activity is coordinated by the essential regulatory agencies and relies on the production of bulk antigen of the selected strain (HA) and raising of sheep antiserum against it, both activities which take time and can encounter technical difficulties.

### Achilles’ Heels of the Current Influenza Vaccines

The success of current influenza vaccination campaigns depends heavily on extensive surveillance and manufacturing resources to ensure timely vaccine delivery. Given that each component of the vaccine is updated every 2 to 3 years on average, it is not too surprising that there are occasional problems. Some of the Achilles’ heels of the current influenza vaccine pipelines and the strategies needed to address them are summarized as follows.

1. Variable efficacy in specific populations. Influenza vaccines are relatively poorly immunogenic and do not induce long-lasting serum antibody titers. In the elderly, waning immunity (immunosenescence) also means poor responsiveness to vaccines. Therefore, strategies are required to improve the immune response to vaccine, especially in various at-risk target populations.
2. Variable virus. Antigenic matching between vaccine strains and circulating strains is critical. Current strategies to address this include improvement of global surveillance and the development of new-generation vaccines that target conserved regions of the virus.
3. Production time frame and manufacturing limitations. The time frame between vaccine strain selection and vaccine delivery is short and allows for few unanticipated delays. The requirement for large quantities of vaccine also places a production burden on the manufacturing process. Strategies are required to improve the growth of conventional vaccine viruses, reduce the production time, improve manufacturing processes, and increase the immunogenicity of vaccine (dose sparing).
4. Limited vaccine availability in resource-limited countries. Although not specific for influenza vaccines, there is great disparity in vaccine availability in countries throughout the world. More scalable platforms and cheaper vaccines that induce longer-lasting immunity are needed to address this need.

## VARIATION ON THE CONVENTIONAL

With the well-accepted limitations and deficiencies in the current influenza vaccine system, substantial resources have been spent trying to improve it. The improvements that are most advanced, many of which are already in use, are those that contribute incremental, but important, advances to the current TIV and LAIV platforms.

### Egg versus Cell Culture

Egg-based vaccine production, although time tested, is a resource- and time-intensive process that is critically dependent on a continuous supply of eggs and the ability of viruses to grow on this substrate. The risk of contamination by avian pathogens in the egg supply or microbial contaminants during processing has previously jeopardized vaccine supplies (68; <http://www.nature.com/news/2004/041004/full/news041004-8.html>). Furthermore, egg supply could be limited in the event of a pandemic, and egg-based vaccines may still pose a theoretical risk of anaphylactic responses in egg-allergic individuals. The ACIP recommends that TIVs be used under medical supervision for individuals with a severe allergy to egg proteins (69).

One strategy to complement the egg-based process is the use of a cell culture platform. The cell culture platform provides the theoretical advantages of scalability, availability, and ease of manipulation from a manufacturing perspective and host compatibility from a biological perspective. Growth of human influenza viruses in cultured cells typically results in fewer adaptive mutations, some of which can change virus antigenicity, than are seen after growth in eggs (70, 71). In addition, cell culture, unlike embryonated eggs, can be cryopreserved, reconstituted, and scaled up at any time. By process improvements such as cell adaptation and the use of bioreactors, vaccine strains can be successfully grown to high yields, although it is not clear if this is universally the case (72, 73). To date, the continuous mammalian cell lines Vero (monkey kidney cells) and MDCK (canine kidney cells) and human-derived PER.C6 cells have been used successfully to prepare seasonal and prepandemic influenza vaccines (74, 75). The MDCK-derived influenza vaccine (Optaflu) is currently licensed in Europe and was shown to be comparable with egg-derived TIV in terms of safety, immunogenicity, and efficacy in children and adults up to 50 years of age (76–79). The U.S. FDA also recently approved Novartis' MDCK-derived vaccine Flucelvax for adults 18 years of age and older (<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm328629.htm>).

The future of cell culture platforms for influenza vaccines relies heavily on reproducibly providing vaccine yields at an acceptable cost; without this, the commercial incentives to switch production systems are minimal.

### Reverse Genetics

A second variation of conventional influenza vaccine production is the implementation of reverse genetics, an approach that utilizes molecular techniques to generate a specific virus phenotype. As transcription of the negative-sense viral RNA is mediated by the viral RNA polymerase complex, any *in vitro* reconstruction strategies for influenza viruses require the presence of active viral polymerase to initiate transcription. In the early systems, this was achieved by transfection of the active ribonucleoprotein complex (RNP) or helper viruses (80), but the development of influenza virus plasmid-based reverse genetic systems in the late 1990s allowed for the generation of influenza viruses from cloned cDNA

(15). To generate cloned reverse genetic viruses, the viral RNA segments are first amplified by PCR and cloned into expression plasmids containing RNA polymerase I and/or II sequence, which drives the transcription and protein expression of the viral cDNA. There are variations of the plasmid-based systems: for example, the 12-plasmid system is comprised of 4 protein expression plasmids to produce the polymerase complex (PB2, PB1, PA, and NP) and 8 plasmids to generate the negative-sense viral RNA segments separately, while the 8-plasmid system has both RNA polymerases I and II in the same plasmid vectors, and it is thus able to produce both viral proteins and RNA simultaneously (81, 82). These plasmids are then transfected into cells, and viable virus can be recovered from the culture supernatant. Other recent modifications to the system include incorporation of multiple transcription cassettes into a single plasmid to improve transfection efficiency and, consequently, virus yield (83, 84). An early proof-of-principle use for the technology was the development of high-growth vaccine seed strains. Strains with the desired genotype could be produced easily without the need for selection systems. Although theoretically useful for production of conventional TIV seed strains, in practice, it has not been possible to accurately predict which gene segments from the master PR8 strain are required for high-level growth of different vaccine viruses, and as such, conventional reassortment procedures have remained preferred (they allow for a number of different gene combinations to be generated). There are, however, two areas where the reverse genetics technologies have proved invaluable. The first area is in the development of reassortant strains for some of the LAIVs. In this case, as the seed viruses are required to contain 6 gene segments from the master strain, which encode the attenuating mutations, and the HA and NA from the target virus, reverse genetics has streamlined the process of seed virus development. The second area of use is where specific mutations have had to be introduced into the virus. For example, reverse genetics was used to produce an attenuated H5N1 vaccine strain that lacks the HA cleavage sequence associated with high-level virulence in avian and mammalian hosts (although proof of its role in humans is lacking) (85). To date, reverse genetics has remained the only working method to produce safe, matching H5 vaccine seed strains.

One limitation to the plasmid-based reverse genetic systems, however, is the host cell specificity of the RNA Pol I promoter, which is used to produce the negative-sense viral RNA in transfected cells. The promoter is relatively specific to RNA polymerases of human or primate origin, limiting the practical application of the system to human/primate cell lines. The approved cell lines for human vaccine production that are compatible for influenza virus growth include MDCK cells, Vero cells, and chicken embryonic fibroblasts (CEFs), but these cells do not have high transfection efficiency. Thus far, the original plasmid system has been applied to generate H5 vaccine strains primarily in Vero cells. Alternative reverse genetics systems using canine- and avian-derived Pol I promoter sequences have been cloned to enable the generation of recombinant viruses in MDCK and CEF cells (86, 87). As these modifications develop and as we learn more about specific gene mutations and compatibilities that control virus growth, we expect the use of reverse genetics to become more widespread in the development of influenza vaccines.

## Role of Adjuvants

As discussed above, the relatively poor immunogenicity of split or subunit TIV formulations is of some concern and has been a target for improvement. One way to improve the immunogenicity of influenza vaccines, especially in vulnerable populations, is via adjuvants, which are compounds that can enhance the immune response elicited by an antigen. Generally, adjuvants exert their effect by improving antigen delivery or targeting specific immune pathways to improve the immunogenicity of vaccines (88). Currently licensed adjuvants for vaccine usage include aluminum salt (alum) and the squalene oil-in-water emulsion systems MF59 (Novartis) and AS03 (GlaxoSmithKline). MF59 has been licensed for use with seasonal vaccines in the elderly in some countries, while AS03 has been used in conjunction with monovalent preparations of inactivated 2009 pandemic H1N1 and prepandemic H5N1 virus vaccines (<http://www.ema.europa.eu/>).

Although alum has been successfully used as an adjuvant in many other vaccines, alum-adjuvanted influenza virus H5N1 vaccines have shown either no improvement or only marginal improvement over nonadjuvanted formulations (89, 90). Oil-in-water-adjuvanted vaccines may be more promising, given that the MF59-adjuvanted pandemic H1N1 and H5N1 virus vaccines were able to induce higher antibody titers than nonadjuvanted formulations in naive populations (90–92). Besides boosting antibody titers, oil-in-water adjuvants have also been shown to broaden the immune recognition repertoire in H5 (92–94) and seasonal TIV vaccinees (95–97), generating cross-reactive antibodies as well as stimulating both cellular and humoral immunities. Importantly, adjuvanted vaccines induce a stronger immune response in the elderly (>65 years old) (98–100) and have double the efficacy of unadjuvanted formulations in young children (101). Although adjuvanted vaccines can be associated with more severe reactogenicity, the symptoms are still considered mild and transient (102). The MF59-adjuvanted pandemic vaccine Focetria, marketed by Novartis, was licensed for use in Europe during the 2009 pandemic, and postmarketing data confirmed its safety and tolerability (103, 104). Recent data also indicate that Focetria is safe, well tolerated, and immunogenic in infants between 6 and 23 months of age (105). However, several countries in Europe reported incidences of narcolepsy associated with the AS03-adjuvanted pandemic vaccine Pandemrix (GlaxoSmithKline), but it is not clear whether this effect is due to the vaccine itself or infection with the pandemic strain (106, 107).

Other adjuvants in experimental stages that are being tested with the aim of improving antigen delivery, processing, and recognition are compounds that target the pattern recognition receptors of immune cells (108). These adjuvants can be immunostimulatory DNA sequences (109–111) or bacterium-derived components (112, 113) and are expected to stimulate both arms of the innate and adaptive immune response. For example, Taylor et al. (112) advanced a fusion protein comprising the immunogenic domain of HA (HA1) and the bacterial protein flagellin as a vaccine to a phase II clinical study. Their vaccine was well tolerated and immunogenic in subjects >65 years old, even with just a single 5- $\mu$ g dose.

## Route of Vaccine Delivery

Another approach being explored to increase the immunogenicity of influenza vaccines is to differentially stimulate the immune

system through alternative delivery routes. Such an approach in terms of influenza vaccine delivery is intradermal (i.d.) inoculation, with the rationale of engaging the abundant pool of professional antigen-presenting cells (APCs) in the skin. APCs are efficient at capturing and processing antigens for subsequent presentation in the lymphoid organs, resulting in stimulation of both innate and adaptive immunity (114). In some cases, i.d. vaccines performed better than the conventional intramuscular or subcutaneous vaccines in stimulating a robust immune response (reviewed in reference 115). This approach is especially relevant for the elderly, since in two head-to-head studies, i.d. vaccines were superior to i.m. vaccines in terms of immunogenicity in the elderly (>60 years old) (116, 117). Initial reports on the i.d. delivery of the influenza vaccine in healthy adults showed that it was as efficacious as i.m. vaccines in stimulating an antibody response, even with only half the standard dose of HA (118, 119). A systematic review of clinical studies with i.d. vaccines showed that most studies reported comparable immunogenicity between reduced doses of i.d. vaccines and standard i.m. vaccines (120), suggesting that i.d. vaccination could provide a dose-sparing strategy.

Traditional i.d. delivery requires skill and experience to deliver the vaccine to the right layer of the skin (dermis or epidermis). Recent developments included the use of microneedles for i.d. delivery. Microneedles are submicrometer-length structures that pierce the skin superficially for antigen delivery. There are several types of microneedle delivery systems, including array-type microneedles, coated with antigen, or a single hollow microneedle attached to an injector device that dispenses liquid antigen (121). Microneedles have shown promise in the delivery of vaccines and are reportedly easy to use, painless, and effective, even improving the immunogenicity of DNA vaccines (122). Intanza (or Fluzone-Intradermal in the United States), marketed by Sanofi Pasteur, which uses the hollow-type microneedles attached to a microinjection system with a lower dose of HA, has been licensed for use in the elderly in several countries (123–125) and in the United States since 2011 (Table 1).

## High Dose of Hemagglutinin

Given the poor performance of TIVs in the elderly, Fluzone High-Dose, a new formulation of TIV that contains four times the standard dose of HA, was approved for use in the elderly in the United States in 2010. This vaccine is administered in a single dose and can induce antibody titers equal to or better than those induced by the standard TIV (126). High-dose HA was also shown to improve immunogenicity in HIV-immunocompromised patients, despite their low overall CD4 counts (127), indicating that increasing the antigenic dose can result in a correspondingly increased immune response (128). The high dose, however, may present a manufacturing burden, especially during a pandemic, when demand is anticipated to be high, and, although effective, may prove impractical outside high-risk groups.

## SAME TARGET, DIFFERENT APPROACH

While the discussion above has focused on improving the influenza vaccine pipelines currently in use, such approaches are still limited by factors intrinsic to the TIV and LAIV platforms themselves. As such, it is likely that major improvements to influenza vaccines will come about through development of distinct vaccination platforms. Correspondingly, new vaccine delivery and manufacturing technologies are being investigated for use in pro-



duction of influenza vaccines. These vaccine approaches include the use of vectored or expressed HA antigens and/or targeting of different viral antigens.

### Baculovirus Expression Systems

A relatively advanced technology used to manufacture influenza vaccine is the baculovirus expression vector system (BEVS). Baculoviruses are DNA viruses that infect insects, specifically of the lepidopteran species. During infection, baculoviruses make large amounts of a viral protein, polyhedrin, late in the infection cycle. As this protein is not essential for viral replication, it has been widely utilized as a foreign protein production vehicle. The BEVS relies on the generation of a recombinant baculovirus, in which the polyhedrin gene is replaced with the foreign gene of interest (for more detailed information, see reference 129). Subsequent purification by filtration and chromatographic separation can be used to isolate the protein of interest (130). One caveat to the BEVS is that the use of insect cell lines may not posttranslationally modify the expressed proteins with the same accuracy as mammalian cells, which may affect the function of the expressed protein.

The BEVS was successfully used to produce the licensed human papillomavirus vaccine (131), demonstrating its safety and feasibility for commercial vaccine production. FluBlok (Protein Sciences), a recombinant HA trivalent influenza vaccine derived from the company's proprietary insect SF9 cells (ExpresSF+), has also recently been approved by the FDA for use in persons between 18 and 49 years of age. Because it is produced in insect cells, recombinant HA is not cleaved into its two subunits (HA1 and HA2) and remains as the full-length uncleaved precursor (HA0). Since HA0 retains all the antigenic domains, it is expected that the immunization mechanism will result in immunity comparable to that induced by TIV. FluBlok, however, contains a higher dose of HA (about 3 times more) than the licensed TIV. The major advantages of the baculovirus system are the scalability, quick production, and suitability for production of vaccines against highly pathogenic influenza viruses. Clinical studies in healthy adults showed that FluBlok was well tolerated and induced better antibody responses (albeit at 3 times the antigen dose) than a licensed TIV in adults between 50 and 64 years of age (132, 133) but was not as efficacious in children younger than 5 years of age (134).

### Virus-Like Particles

Virus-like particles (VLPs) are essentially "hollow-core" virus particles formed by the expression and self-assembly of only the viral structural proteins. VLPs retain the morphology and antigenicity of the whole virus, but they are replication incompetent, as they do not have a genomic component. VLPs can also activate innate immunity via pathogen recognition receptors, perhaps because they retain the structural components of the virus (135). In the case of influenza virus, VLPs are most often produced by co-expression of HA, NA, M1, and, sometimes, M2 (136, 137), although HA and NA alone may be sufficient for VLP production (138). Influenza VLPs have been produced from various expression systems, including baculovirus, vaccinia virus, DNA transfection in insects, and even plant-derived systems (reviewed in reference 139). A baculovirus-derived VLP vaccine encoding HA, NA, and M1 induced a broader immune response than a corresponding whole-virion vaccine and had a more dominant Th1 response than a recombinant HA vaccine in mice and ferrets (140).

The ease of manipulation of the VLP composition is a major advantage of the platform. Pushko et al. recently constructed multitypic VLPs incorporating 3 different subtypes. Both the pandemic-subtype VLP (incorporating H5N1, H7N2, and H2N3) and seasonal VLP (incorporating circulating strains) induced neutralizing antibodies and protected ferrets from lethal challenge (141). VLPs based on non-influenza virus proteins but incorporating influenza virus peptides have also been developed (142). VLP vaccines, although promising, are still restricted mostly to animal studies, and only two vaccines against the pandemic H1N1 and H5N1 viruses have been tested in humans. From a manufacturing perspective, VLP-based vaccines can be produced rapidly and are cost-effective, safe, and scalable. In a proof-of-concept study, Lopez-Macias described the production of a baculovirus-expressed VLP vaccine to be tested in the field within 12 weeks of the start of the 2009 pandemic (143). A phase II study in 18- to 60-year-olds showed that the vaccine induced protective titers and seroconversion at a single HA dose of 15 µg in most study participants (144). Since there was no head-to-head comparison in this particular study, further work must be conducted to assess the induced immunity compared to that induced by the standard TIV.

### Virus Vector Approaches

As the protective antigens of influenza virus are well described, generation of influenza vaccines has been explored in almost all vectored viral systems. Adenovirus, poxvirus, parainfluenza virus, and alphavirus systems are all being developed as influenza vaccine vectors (145–148), although most have not advanced past preclinical studies. A major perceived advantage of some of these viral vectors is direct delivery to the mucosal site, which mimics the process of natural influenza virus infection without the presence of the actual virus. Furthermore, it is a safe approach to engineer vaccines for the highly pathogenic subtypes. In one of the few phase I studies reported, the adenovirus-vectored H5 vaccine was also immunogenic in humans when delivered by the epicutaneous route, although the potency was found to be inferior to that of intranasal delivery (149). Following on this, a larger dose-escalation phase I clinical study with intranasal delivery was initiated, but the outcome of that study has not yet been reported (<http://clinicaltrials.gov/ct2/show/record/NCT00755703>).

Although most of the approaches to date have used expressed HA as the primary antigen, it is possible that virus-vectored vaccines may be particularly well suited to target some of the other viral targets under development (150). Indeed, as discussed in the section on CTL vaccines, the poxvirus vector was used successfully as the delivery vehicle to induce a T-cell response to NP and M in vaccinated subjects (151). Since there are limited data on their efficacy in humans, it is difficult to ascertain if these vectored approaches would fare better than current vaccines.

### DNA Vaccines

Although by no means a new technology, DNA vaccines are also being developed for the control of influenza. Many of the theoretical benefits of nucleic acid-based vaccines, such as rapid production and ease of immunogen exchange, are appealing in terms of influenza vaccination. As a consequence, many DNA vaccine formulation and delivery systems have been applied to preclinical influenza vaccines. In one example of many, mice immunized with linear expression cassettes encoding the M and NP antigens

via electroporation survived lethal challenge with a heterologous H5 strain better than did i.d. vaccinated mice (152).

Influenza virus DNA vaccines have also advanced to clinical trials. In small phase I studies, an H5 HA-based DNA vaccine was assessed in terms of immunogenicity after vaccination by different delivery routes (intramuscular and intradermal) (153). All 3 doses of the vaccine were well tolerated and immunogenic, with only minor differences between routes. In another study, H5 DNA vaccine primed for a superior response when boosted by the monovalent H5 vaccine (MIV), compared to the MIV-MIV prime-boost approach (154). Such a priming strategy appears to be a particularly strong niche for DNA vaccines and may counteract some of the issues associated with their intrinsic poor immunogenicity as a stand-alone vaccine platform. Others have looked to adjuvanted DNA vaccines to overcome immunogenicity problems. In a double-blind, placebo-controlled, phase I trial, Smith and colleagues showed that a Vaxfectin (a cationic lipid-based adjuvant)-formulated H5 HA DNA vaccine was well tolerated and provided protective responses in up to 67% of recipients, findings comparable with responses typically seen with MIV recipients (155). Promising results from clinical studies with a different adjuvanted DNA vaccine combined with a human challenge component (156) suggest that influenza virus DNA vaccines are very much still worthy of further investment and evaluation.

The most recent variation to the theme of nucleic acid-based vaccines is the mRNA-based vaccine. Compared to DNA vaccines, RNA vaccines do not require translocation to the nucleus to achieve protein expression, which in theory should increase the efficiency of antigen expression. In addition, RNA vaccines would be degraded more rapidly than DNA vaccines and, as such, pose no risk of chromosomal integration with the host genome. Petsch and colleagues showed that a stabilized mRNA vaccine formulation, delivered intradermally, was immunogenic and protective in various animal models (157).

## DIFFERENT TARGET, DIFFERENT APPROACH

While many of the newer approaches for delivering influenza virus antigens can accommodate any viral protein or peptide, most proof-of-concept studies have been conducted with HA. While HA-based immunity is potent and well described, and improving its delivery an important task, a true overhaul of influenza vaccination requires a search for more conserved antigens. The discovery of a protective “universal” influenza vaccine would essentially remove many of the major issues associated with influenza vaccination. As the vaccine would not need to be updated, the vaccine could be produced year round with a timetable set by manufacturers and not the virus itself. While the search for a universal influenza vaccine is far from over, some more conserved viral epitopes have been evaluated as vaccine targets.

### M2e-Based Vaccines


Perhaps the most explored universal influenza vaccine target is the extracellular domain of the M2 protein (M2e). M2e has a number of very attractive traits, including its relative conservation across viral strains and its linear peptide nature. The M2 protein is a tetrameric integral membrane protein that forms a minor component of the virus envelope. M2e is exposed on the virion surface, although its virion-associated form is poorly immunogenic (158). Slepishkin et al. (159) provided the earliest support for the protective nature of the anti-M2 antibody, showing that mice vacci-

nated with baculovirus-derived M2 were protected from lethal challenge with H1N1 and H3N2 subtype viruses. To improve immunogenicity, subsequent modifications to the M2-based vaccines have included addition of adjuvants and genes that target and improve immune function and expression on VLP or liposomal platforms (reviewed in reference 139). Although the exact mechanism of M2e-specific immunity is not entirely clear, M2 antibodies do not neutralize the virus, and there is some evidence that they instead function through an antibody-dependent cell cytotoxicity-dependent and/or Fc-macrophage interaction process (160, 161). While there are ample proof-of-concept studies for a protective effect of anti-M2e immunity in mice, extension of these studies to other animals, including ferrets and primates, has been disappointing (162). Nevertheless, a small phase I trial of an M2e-flagellin-conjugated vaccine has been conducted in healthy adults, with a 4-fold increase in M2e titers observed (163). A major challenge for future clinical evaluation of M2e platforms will be the determination of immune correlates of protection.

### Cytotoxic T-Lymphocyte-Inducing Vaccines

As cytotoxic T lymphocytes (CTLs) have a tendency to target more conserved influenza virus proteins, there have been several approaches to increase their numbers through vaccination. Unlike antibody-mediated responses, CTL responses to influenza virus infection are heterotypic, since they are induced mainly by the internal viral proteins (26, 164, 165). Like M2 antibodies, CTL responses do not prevent initial infection but, once primed, exert their effector function on infected cells to aid in recovery and restrict disease progression. In serologically naive humans, a robust CTL response is crucial for early clearance of the virus (166). CTLs are believed to clear the virus mainly through CD8<sup>+</sup> T-cell-granule-mediated cytotoxicity (167), but CD4<sup>+</sup> T cells are important in the subsequent generation and maintenance of memory T cells (168, 169). The current rationale for using CTL vaccines is to provide baseline immunity in the population which may be protective against a newly emerging pandemic virus. While CTL immunity on its own is unlikely to prevent infection and perhaps disease, it could substantially reduce mortality. A key issue with CTL vaccines, however, is that they need to incorporate an epitope that can be recognized universally by all major histocompatibility complex (MHC) subclasses. Assarsson et al. showed that although epitope recognition varied across individuals, it is possible to identify epitope regions that are recognized by all 6 HLA super-types, which should cover most of the major global ethnicities (170). Their study and a study by Lee et al. (171) identified highly conserved epitopes in the M1, NP, and PB1 proteins from more than 17 strains across 6 different subtypes that are targeted by CD4<sup>+</sup> and CD8<sup>+</sup> T cells.

Another factor that can affect the performance of CTL vaccines is epitope immunodominance, in which the CTL response is focused on one or a select few epitopes (172). CTLs recognize epitopes in a hierarchical manner, which is dependent on many factors (reviewed in reference 173). If the CTL vaccine epitope is immunodominant, it is likely to reduce the breadth of response in primed (i.e., vaccinated) individuals. The choice of epitope can also alter the outcome of the response, depending on the binding avidity of the T-cell antigen receptors (TCRs) with the MHC peptide (174). The mode of delivery for CTL-based vaccines must also be considered. To induce a strong CD8<sup>+</sup> T-cell response, the antigen must be processed through the MHC class I processing path-



**FIG 2** (A) Crystal structure of the hemagglutinin (HA) trimer. Shown in this figure is a group 1 HA (H1 subtype) (Protein Data Bank [PDB] accession number 3LGZ), and only one monomer is colored for clarity. The receptor-binding domain (yellow spheres) and the antigenic sites (for H1N1, Sa [blue], Sb [cyan], Cb [magenta], Ca2 [white], and Ca1 [orange]) are all located within the globular head of the protein. The stalk region, consisting of long alpha-helix loops (in red) and the fusion peptide, is more conserved across the different subtypes and plays an important role in the fusion process during virus uncoating. Epitopes/regions in the stalk region that induce broadly cross-reactive antibodies to group 1 (circled in blue) and both group 1 and 2 (circled in red) have been identified (as indicated). (B) A group 2 HA monomer (H3 subtype) (modified from data reported under PDB accession number 3DSY), with the group-reactive epitope highlighted in magenta. References are indicated in parentheses.

way of dendritic cells (DCs). During infection, the viral antigen is loaded onto DCs by direct entry of the virus or through uptake of infected cells undergoing apoptosis (175). Hence, CTL responses during vaccination differ: LAIV induces a strong CD8<sup>+</sup> T-cell response, whereas the conventional subunit TIV is less effective than the whole-virus vaccine at inducing CTLs (166). Therefore, the design and execution of a successful CTL-based vaccination approach are crucial and should incorporate all of these considerations. Strategies that have been used for antigen delivery include the use of viral vectors (176, 177), liposomes, and virosomes (178) as well as the lipid/adjuvant-immunostimulatory complex (ISCOM)-based particulate delivery platform (179, 180). Most CTL vaccines are currently designed to target conserved T-cell epitopes in the M or NP protein, and two CTL vaccines have already reached clinical testing in humans (150, 181). Preliminary data from a phase II trial based on a vaccinia virus-vectored (poxvirus) vaccine suggest higher levels of stimulation of T-cell responses and protection in vaccinees than in controls (151). Perhaps, the greatest potential for CTL-inducing influenza vaccines is as a complement to antibody-producing approaches.

### Cross-Reactive HA Stalk Antibodies

The newest class of “universal” influenza vaccine in development is the cross-reactive HA stalk antibodies. The 16 subtypes of HA are classified into 2 major phylogenetic groups, group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16) and group 2 (H3, H4, H7, H10, H14, and H15), with less than 40% amino acid similarity between the groups (182–184). While it has long been known that cross-reactive antibodies that target the HA stalk can be induced, developments and the production of human monoclonal antibodies (MAbs) have rejuvenated this area. Broadly neutralizing antibodies (bnAbs) that could neutralize group 1 viruses were detected in a human antibody library (185), in immune memory B cells of vaccinees (186), as well as in survivors of H5N1 infections (187). These MAbs bound to the conserved region in the HA stalk that is crucial for membrane fusion and less sensitive to immune pressures (185). Subsequent studies identified similar bnAbs for group 2 viruses (188) and eventually both group 1 and 2 viruses (189) binding to similar but distinct domains in the stalk region (summarized in Fig. 2). It is interesting to note that these bnAbs have been identified under different circumstances: naturally oc-



curing (although with low prevalence) (190, 191), induced because of “original antigenic sin” (a phenomenon whereby the immune system preferentially reacts to epitopes that it has previously encountered at the expense of those on the immunizing antigen) (192), or after vaccination (193).

The identification of these antibodies, which are produced in only small amounts after infection, has led to attempts to induce them to protective levels through vaccination strategies. Steel et al. made a VLP-based “headless” stalk construct (194), and Bommakanti et al. made an *Escherichia coli*-expressed truncated HA2 protein (195). Both constructs protected mice from homologous lethal challenge, with the VLP-based construct showing improved breadth of reactivity against multiple group 1 subtypes (194). Stalk-specific synthetic peptides spanning the long alpha-helix region (residues 76 to 130, based on H3 numbering) also protected mice from H1, H3, and H5 virus challenge, even in passive-transfer experiments (196).

It is of note, however, that more recent publications have found cross-reactive epitopes outside the stalk region. Cross-reactive neutralizing antibodies that recognize the globular head (191) as well the receptor-binding pocket (197) have been identified, suggesting that there are regions on the HA1 domain that can be targeted for a universal vaccine. The identification of conserved domains across all influenza virus subtypes provides an exciting prospect for the development of a universal vaccine; the challenge remains in designing a vaccine that can induce these broadly reactive antibodies to sufficiently protective levels in humans.

## PERSPECTIVES

Although recent meta-analyses have questioned the efficacy of the current TIV in some populations and influenza seasons (60), the collaborative mechanism that is required for its yearly production has been refined over decades. Future improvement will require novel approaches to both vaccine formulation and manufacturing processes. Although fostering of such approaches is a worthy public health endeavor, transformative changes to the system and tipping of the virus-vaccine battle firmly in favor of the vaccine will require the identification of more conserved and protective vaccine antigens. The most promising approaches currently in development are arguably those targeting conserved HA epitopes. The unknowns in this approach are whether the antibodies under investigation will be potent enough for a seasonal vaccine and, even if so, whether their levels can be induced to substantial degrees. The coming years should answer these questions and see other novel approaches trialed, with outcomes that can hopefully improve on the current influenza vaccine platform.

## ACKNOWLEDGMENTS

We thank Vani Shanker for editorial assistance and Sun-Woo Yoon and Mark Zanin for assistance with figure generation.

We are supported financially by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (contract no. HHSN266200700005C), and by the American Lebanese Syrian Associated Charities.

## REFERENCES

- Centers for Disease Control and Prevention. 2010. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. *MMWR Morb. Mortal. Wkly. Rep.* 59:1057–1062.
- Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox

- NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. *JAMA* 292:1333–1340.
- Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, Simmerman JM, Gordon A, Sato M, Howie S, Krishnan A, Ope M, Lindblade KA, Carosone-Link P, Lucero M, Ochieng W, Kamimoto L, Dueger E, Bhat N, Vong S, Theodoratou E, Chittaganpitch M, Chimah O, Balmaseda A, Buchy P, Harris E, Evans V, Katayose M, Gaur B, O’Callaghan-Gordo C, Goswami D, Arvelo W, Venter M, Briese T, Tokarz R, Widdowson MA, Mounts AW, Breiman RF, Feikin DR, Klugman KP, Olsen SJ, Gessner BD, Wright PF, Rudan I, Broor S, Simoes EA, Campbell H. 2011. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. *Lancet* 378:1917–1930.
- Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S. 2012. Immunosenescence and challenges of vaccination against influenza in the aging population. *Aging Dis.* 3:68–90.
- Taubenberger JK, Morens DM. 2006. 1918 influenza: the mother of all pandemics. *Emerg. Infect. Dis.* 12:15–22.
- Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Molbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. 2012. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *Lancet Infect. Dis.* 12:687–695.
- FAO. 2011. Approaches to controlling, preventing and eliminating H5N1 highly pathogenic avian influenza in endemic countries. *Animal Production and Health Paper no. 171*. FAO, Rome, Italy. <http://www.fao.org/docrep/014/i2150e/i2150e.pdf>.
- Moriuchi H, Katsushima N, Nishimura H, Nakamura K, Numazaki Y. 1991. Community-acquired influenza C virus infection in children. *J. Pediatr.* 118:235–238.
- Estabragh ZR, Mamas MA. 6 March 2013. The cardiovascular manifestations of influenza: a systematic review. *Int. J. Cardiol.* [Epub ahead of print.] doi:10.1016/j.ijcard.2013.01.274.
- Hui DS. 2008. Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. *Respirology* 13(Suppl 1):S10–S13. doi:10.1111/j.1440-1843.2008.01247.x.
- Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. *N. Engl. J. Med.* 362:1708–1719.
- Ekstrand JJ, Herbener A, Rawlings J, Turney B, Ampofo K, Korgenski EK, Bonkowsky JL. 2010. Heightened neurologic complications in children with pandemic H1N1 influenza. *Ann. Neurol.* 68:762–766.
- Wright PF, Neuman G, Kawaoka Y. 2007. Orthomyxoviruses, p 1691–1740. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), *Fields virology*, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
- Tong S, Li Y, Rivallier P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. 2012. A distinct lineage of influenza A virus from bats. *Proc. Natl. Acad. Sci. U. S. A.* 109:4269–4274.
- Zaman M, Ashraf S, Dreyer NA, Toovey S. 2011. Human infection with avian influenza virus, Pakistan, 2007. *Emerg. Infect. Dis.* 17:1056–1059.
- Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM, Chunsutthiwat S. 2005. Probable person-to-person transmission of avian influenza A (H5N1). *N. Engl. J. Med.* 352:333–340.
- Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. *Nature* 486:420–428.
- Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelz-



- waan GF, Osterhaus AD, Fouchier RA. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. *Science* 336:1534–1541.
19. Taubenberger JK, Kash JC. 2010. Influenza virus evolution, host adaptation, and pandemic formation. *Cell Host Microbe* 7:440–451.
  20. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, Valleron AJ. 2008. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am. J. Epidemiol.* 167:775–785.
  21. Pang IK, Iwasaki A. 2011. Inflammasomes as mediators of immunity against influenza virus. *Trends Immunol.* 32:34–41.
  22. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. 2011. Immune responses to influenza virus infection. *Virus Res.* 162:19–30.
  23. Yap KL, Ada GL, McKenzie IF. 1978. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. *Nature* 273:238–239.
  24. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. 2000. Human memory CTL response specific for influenza A virus is broad and multi-specific. *Hum. Immunol.* 61:438–452.
  25. Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH. 2009. HLA class I molecules consistently present internal influenza epitopes. *Proc. Natl. Acad. Sci. U. S. A.* 106:540–545.
  26. Kees U, Krammer PH. 1984. Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. *J. Exp. Med.* 159:365–377.
  27. Ge X, Tan V, Bollyky PL, Standifer NE, James EA, Kwok WW. 2010. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. *J. Virol.* 84:3312–3319.
  28. Babon JA, Cruz J, Ennis FA, Yin L, Terajima M. 2012. A human CD4+ T cell epitope in the influenza haemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus. *J. Virol.* 86:9233–9243.
  29. Han T, Marasco WA. 2011. Structural basis of influenza virus neutralization. *Ann. N. Y. Acad. Sci.* 1217:178–190.
  30. Styk B, Russ G, Polakova K. 1979. Antigenic glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. III. Reactivity with human convalescent sera. *Acta Virol.* 23:1–8.
  31. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. *J. Clin. Invest.* 120:1663–1673.
  32. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. 1999. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. *Virology* 254:138–146.
  33. Hampson AW, Osterhaus AD, Pervikov Y, Kieny MP. 2006. Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6–7 December 2005. *Vaccine* 24:4897–4900.
  34. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. 2009. Comparative efficacy of inactivated and live attenuated influenza vaccines. *N. Engl. J. Med.* 361:1260–1267.
  35. Salk J, Salk D. 1977. Control of influenza and poliomyelitis with killed virus vaccines. *Science* 195:834–847.
  36. Francis T, Jr. 1953. Vaccination against influenza. *Bull. World Health Organ.* 8:725–741.
  37. Kitchen LW, Vaughn DW. 2007. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. *Vaccine* 25:7017–7030.
  38. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm. Rep.* 59(RR8):1–62.
  39. Mereckiene J, Cotter S, Nicoll A, Levy-Bruhl D, Ferro A, Tridente G, Zandoni G, Berra P, Salmaso S, O'Flanagan D, VENICE Project Gatekeepers Group. 2008. National seasonal influenza vaccination survey in Europe, 2008. *Euro Surveill.* 13(43):pii=19017. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19017>.
  40. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. 2010. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. *Vaccine* 28:3929–3935.
  41. Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ. 2011. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. *Clin. Vaccine Immunol.* 18:1358–1364.
  42. Duxbury AE, Hampson AW, Sievers JG. 1968. Antibody response in humans to deoxycholate-treated influenza virus vaccine. *J. Immunol.* 101:62–67.
  43. Laver WG, Webster RG. 1976. Preparation and immunogenicity of an influenza virus haemagglutinin and neuraminidase subunit vaccine. *Virology* 69:511–522.
  44. Bachmayer H, Liehl E, Schmidt G. 1976. Preparation and properties of a novel influenza subunit vaccine. *Postgrad. Med. J.* 52:360–367.
  45. Brady MI, Furminger IG. 1976. A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity. *J. Hyg. (Lond.)* 77:173–180.
  46. Brady MI, Furminger IG. 1976. A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins. *J. Hyg. (Lond.)* 77:161–172.
  47. Parkman PD, Hopps HE, Rastogi SC, Meyer HM, Jr. 1977. Summary of clinical trials of influenza virus vaccines in adults. *J. Infect. Dis.* 136(Suppl):S722–S730.
  48. Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. 1977. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. *J. Infect. Dis.* 136:623–632.
  49. Gross PA, Ennis FA. 1977. Influenza vaccine: split-product versus whole-virus types—how do they differ. *N. Engl. J. Med.* 296:567–568.
  50. Reed C, Meltzer MI, Finelli L, Fiore A. 2012. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. *Vaccine* 30:1993–1998.
  51. Belshe RB. 2010. The need for quadrivalent vaccine against seasonal influenza. *Vaccine* 28(Suppl 4):D45–D53. doi:10.1016/j.vaccine.2010.08.028.
  52. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. 2013. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. *Vaccine* 31:770–776.
  53. Maassab HF. 1967. Adaptation and growth characteristics of influenza virus at 25 degrees C. *Nature* 213:612–614.
  54. Maassab HF, Bryant ML. 1999. The development of live attenuated cold-adapted influenza virus vaccine for humans. *Rev. Med. Virol.* 9:237–244.
  55. Maassab HF, Heilman CA, Herlocher ML. 1990. Cold-adapted influenza viruses for use as live vaccines for man. *Adv. Biotechnol. Processes* 14:203–242.
  56. Murphy BR, Park EJ, Gottlieb P, Subbarao K. 1997. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. *Vaccine* 15:1372–1378.
  57. Parkin NT, Chiu P, Coelingh K. 1997. Genetically engineered live attenuated influenza A virus vaccine candidates. *J. Virol.* 71:2772–2778.
  58. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, Garcia-Sastre A, Palese P. 2000. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. *Proc. Natl. Acad. Sci. U. S. A.* 97:4309–4314.
  59. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J. 2009. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. *Vaccine* 27:1101–1110.
  60. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect. Dis.* 12:36–44.
  61. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. 2006. Avian flu: influenza virus receptors in the human airway. *Nature* 440:435–436.
  62. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. 2006. H5N1 virus attachment to lower respiratory tract. *Science* 312:399. doi:10.1126/science.1125548.
  63. Karron RA, Talaat K, Luke C, Callahan K, Thumar B, D'Irenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K, Chen G, Lamirande E,

- Coelingh K, Jin H, Murphy BR, Kemble G, Subbarao K. 2009. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. *Vaccine* 27:4953–4960.
64. Alexandrova GI, Budilovsky GN, Koval TA, Polezhaev FI, Garmashova LM, Ghendon Yu Z, Romanova YR, Smorodintsev AA. 1986. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. *Vaccine* 4:114–118.
  65. Ghendon YZ, Polezhaev FI, Lisovskaya KV, Medvedeva TE, Alexandrova GI, Klimov AI. 1984. Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. *Infect. Immun.* 44:730–733.
  66. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, Grohmann G, Hay A, Kelso A, Klimov A, Odagiri T, Smith D, Russell C, Tashiro M, Webby R, Wood J, Ye Z, Zhang W. 2010. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. *Vaccine* 28:1156–1167.
  67. Gerdil C. 2003. The annual production cycle for influenza vaccine. *Vaccine* 21:1776–1779.
  68. McQuillan L, Daley MF, Stokley S, Crane LA, Beaty BL, Barrow J, Babel C, Dickinson LM, Kempe A. 2009. Impact of the 2004–2005 influenza vaccine shortage on pediatric practice: a national survey. *Pediatrics* 123:e186–e192. doi:10.1542/peds.2008-1035.
  69. Centers for Disease Control and Prevention. 2012. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2012–13 influenza season. *MMWR Morb. Mortal. Wkly. Rep.* 61:613–618.
  70. Wang ML, Katz JM, Webster RG. 1989. Extensive heterogeneity in the hemagglutinin of egg-grown influenza viruses from different patients. *Virology* 171:275–279.
  71. Schild GC, Oxford JS, de Jong JC, Webster RG. 1983. Evidence for host-cell selection of influenza virus antigenic variants. *Nature* 303:706–709.
  72. Genzel Y, Dietzsch C, Rapp E, Schwarzer J, Reichl U. 2010. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. *Appl. Microbiol. Biotechnol.* 88:461–475.
  73. Audsley JM, Tannock GA. 2008. Cell-based influenza vaccines: progress to date. *Drugs* 68:1483–1491.
  74. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytendaele F. 2001. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. *Vaccine* 19:2716–2721.
  75. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Hoschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. 2009. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. *Vaccine* 27:1889–1897.
  76. Vesikari T, Forsten A, Herbing KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. 2012. Safety and immunogenicity of an MF59-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. *Vaccine* 30:1388–1396.
  77. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. 2009. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential phase I and phase II clinical trial. *Vaccine* 27:786–791.
  78. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. 2009. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. *J. Infect. Dis.* 200:849–857.
  79. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. 2009. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. *J. Infect. Dis.* 200:841–848.
  80. Garcia-Sastre A, Palese P. 1993. Genetic manipulation of negative-strand RNA virus genomes. *Annu. Rev. Microbiol.* 47:765–790.
  81. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc. Natl. Acad. Sci. U. S. A.* 97:6108–6113.
  82. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. 1999. Generation of influenza A viruses entirely from cloned cDNAs. *Proc. Natl. Acad. Sci. U. S. A.* 96:9345–9350.
  83. Neumann G, Fujii K, Kino Y, Kawaoka Y. 2005. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. *Proc. Natl. Acad. Sci. U. S. A.* 102:16825–16829.
  84. Zhang X, Kong W, Ashraf S, Curtiss R, III. 2009. A one-plasmid system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine. *J. Virol.* 83:9296–9303.
  85. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehag JE, Tuomanen EI, Webster RG. 2004. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. *Lancet* 363:1099–1103.
  86. Murakami S, Horimoto T, Mai LQ, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. 2008. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. *J. Virol.* 82:10502–10509.
  87. Massin P, Rodrigues P, Marasescu M, van der Werf S, Naffakh N. 2005. Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells. *J. Virol.* 79:13811–13816.
  88. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work. *Immunity* 33:492–503.
  89. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. *Lancet* 367:1657–1664.
  90. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. 2008. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. *J. Infect. Dis.* 197:667–675.
  91. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. 2009. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. *N. Engl. J. Med.* 361:2424–2435.
  92. Frapapan E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. 2010. A heterologous MF59-adjuvanted H5N1 pre-pandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. *Clin. Vaccine Immunol.* 17:1817–1819.
  93. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanna P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. 2009. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. *PLoS One* 4:e4384. doi:10.1371/journal.pone.0004384.
  94. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I. 2009. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted pre-pandemic vaccine. *Proc. Natl. Acad. Sci. U. S. A.* 106:7962–7967.
  95. Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, Busana MC, Bertonecello C, Trivello R. 2010. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. *Clin. Dev. Immunol.* 2010:517198. doi:10.1155/2010/517198.
  96. Camilloni B, Neri M, Lepri E, Iorio AM. 2009. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. *Vaccine* 27:4099–4103.
  97. Ansaldo F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P. 2008. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. *Vaccine* 26:1525–1529.
  98. Gasparini R, Pozzi T, Montomoli E, Frapapan E, Senatore F, Minutello M, Podda A. 2001. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. *Eur. J. Epidemiol.* 17:135–140.
  99. Frey S, Poland G, Percell S, Podda A. 2003. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. *Vaccine* 21:4234–4237.
  100. Iob A, Brianti G, Zamparo E, Gallo T. 2005. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a

- non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. *Epidemiol. Infect.* 133:687–693.
101. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R. 2011. Oil-in-water emulsion adjuvant with influenza vaccine in young children. *N. Engl. J. Med.* 365:1406–1416.
  102. Wijnans L, de Bie S, Dieleman J, Bonhoeffer J, Sturkenboom M. 2011. Safety of pandemic H1N1 vaccines in children and adolescents. *Vaccine* 29:7559–7571.
  103. Banzhoff A, Haertel S, Praus M. 2011. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. *Hum. Vaccin.* 7:539–548.
  104. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. 2009. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. *Vaccine* 27:6959–6965.
  105. Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N. 2011. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. *Pediatrics* 127:e1161–1168.
  106. Montastruc JL, Durrieu G, Rascol O. 2011. Pandemrix, (H1N1)v influenza and reported cases of narcolepsy. *Vaccine* 29:2010. doi:10.1016/j.vaccine.2010.12.092.
  107. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsen P, Saarenpaa-Heikkila O, Kilpi T. 2012. AS03 adjuvanted A/H1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One* 7:e33536. doi:10.1371/journal.pone.0033536.
  108. Levitz SM, Golenbock DT. 2012. Beyond empiricism: informing vaccine development through innate immunity research. *Cell* 148:1284–1292.
  109. Fang Y, Rowe T, Leon AJ, Banner D, Danesh A, Xu L, Ran L, Bosinger SE, Guan Y, Chen H, Cameron CC, Cameron MJ, Kelvin DJ. 2010. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. *J. Virol.* 84:8369–8388.
  110. Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De Gregorio E. 2012. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. *J. Immunol.* 188:3088–3098.
  111. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, Wang Y, Venzon D, Epstein SL, Segal DM. 2011. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. *J. Immunol.* 186:2422–2429.
  112. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. 2011. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SL.) *Vaccine* 29:4897–4902.
  113. de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K. 2012. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. *Vaccine* 30:4884–4891.
  114. Romani N, Flacher V, Tripp CH, Sparber F, Ebner S, Stoitner P. 2012. Targeting skin dendritic cells to improve intradermal vaccination. *Curr. Top. Microbiol. Immunol.* 351:113–138.
  115. Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, Icardi G. 2011. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. *Hum. Vaccin.* 7(Suppl):29–40. doi:10.4161/hv.7.0.14560.
  116. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M. 2008. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. *J. Infect. Dis.* 198:650–658.
  117. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. 2009. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. *Vaccine* 27:7304–7312.
  118. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G. 2004. Serum antibody responses after intradermal vaccination against influenza. *N. Engl. J. Med.* 351:2286–2294.
  119. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. 2004. Dose sparing with intradermal injection of influenza vaccine. *N. Engl. J. Med.* 351:2295–2301.
  120. Young F, Marra F. 2011. A systematic review of intradermal influenza vaccines. *Vaccine* 29:8788–8801.
  121. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. 2009. Microneedle-based vaccines. *Curr. Top. Microbiol. Immunol.* 333:369–393.
  122. Song JM, Kim YC, Eunju O, Compans RW, Prausnitz MR, Kang SM. 2012. DNA vaccination in the skin using microneedles improves protection against influenza. *Mol. Ther.* 20:1472–1480.
  123. Eizenberg P, Booy R, Naser N, Mason G, Stambouliau D, Weber F. 2011. Acceptance of Intanza 9 mug intradermal influenza vaccine in routine clinical practice in Australia and Argentina. *Adv. Ther.* 28:640–649.
  124. Dhont PA, Albert A, Brenders P, Podwapinska A, Pollet A, Scheveneels D, Tihon F, Verheyden I, Victor J, Samson SI. 2012. Acceptability of Intanza 15 mug intradermal influenza vaccine in Belgium during the 2010–2011 influenza season. *Adv. Ther.* 29:562–577.
  125. Prymula R, Usluer G, Altinel S, Sichova R, Weber F. 2012. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. *Adv. Ther.* 29:41–52.
  126. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. 2009. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *J. Infect. Dis.* 200:172–180.
  127. El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keitel WA. 2012. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. *J. Infect. Dis.* 205:703–712.
  128. Overton ET. 2012. Sometimes, more is better. *J. Infect. Dis.* 205:697–699.
  129. Jarvis DL. 2009. Baculovirus-insect cell expression systems. *Methods Enzymol.* 463:191–222.
  130. Cox MM. 2012. Recombinant protein vaccines produced in insect cells. *Vaccine* 30:1759–1766.
  131. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuid A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet* 364:1757–1765.
  132. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. 2011. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine* 29:7733–7739.
  133. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. 2011. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. *Vaccine* 29:2272–2278.
  134. King JC, Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. 2009. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. *Vaccine* 27:6589–6594.
  135. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM. 2006. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. *J. Virol.* 80:9134–9143.
  136. Latham T, Galarza JM. 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. *J. Virol.* 75:6154–6165.
  137. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. *Vaccine* 23:5751–5759.
  138. Chen BJ, Leser GP, Morita E, Lamb RA. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. *J. Virol.* 81:7111–7123.



139. Kang SM, Song JM, Compans RW. 2011. Novel vaccines against influenza viruses. *Virus Res.* 162:31–38.
140. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrillo V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. *Vaccine* 25:3871–3878.
141. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM. 2011. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. *Vaccine* 29:5911–5918.
142. Savard C, Laliberte-Gagne ME, Babin C, Bolduc M, Guerin A, Drouin K, Forget MA, Majeau N, Lapointe R, Leclerc D. 2012. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. *Vaccine* 30:2535–2542.
143. Lopez-Macias C. 2012. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. *Hum. Vaccin. Immunother.* 8:411–414.
144. Lopez-Macias C, Ferat-Orsorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G. 2011. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. *Vaccine* 29:7826–7834.
145. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK, Sambhara S. 2006. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. *Lancet* 367:475–481.
146. Mooney AJ, Li Z, Gabbard JD, He B, Tompkins SM. 2013. Recombinant PIV5 vaccine encoding the influenza hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice. *J. Virol.* 87:363–371.
147. Yang SG, Wo JE, Li MW, Mi FF, Yu CB, Lv GL, Cao HC, Lu HF, Wang BH, Zhu H, Li LJ. 2009. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human avian influenza (H5N1). *Vaccine* 27:7451–7458.
148. Kreijtz JH, Suezter Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF. 2009. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. *Vaccine* 27:6296–6299.
149. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmetts CA, Tang DC. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. *Vaccine* 23:1029–1036.
150. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC. 2011. Potent CD8+ T-cell immunogenicity in humans of a novel hetero-subtypic influenza A vaccine, MVA-NP+M1. *Clin. Infect. Dis.* 52:1–7.
151. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC. 2012. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. *Clin. Infect. Dis.* 55:19–25.
152. Shen X, Soderholm J, Lin F, Kobinger G, Bello A, Gregg DA, Broderick KE, Sardesai NY. 2012. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. *Vaccine* 30:6946–6954.
153. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS. 2012. Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. *Clin. Vaccine Immunol.* 19:1792–1797.
154. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS. 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. *Lancet Infect. Dis.* 11:916–924.
155. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsabouloy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB. 2010. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. *Vaccine* 28:2565–2572.
156. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Mant T, Nolan A, Zambon M, Ellis J, Beadle J, Loudon PT. 2009. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. *Vaccine* 27:2506–2512.
157. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T. 2012. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. *Nat. Biotechnol.* 30:1210–1216.
158. Rossman JS, Lamb RA. 2011. Influenza virus assembly and budding. *Virology* 411:229–236.
159. Slepishkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. 1995. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. *Vaccine* 13:1399–1402.
160. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. *J. Immunol.* 172:5598–5605.
161. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. *J. Immunol.* 186:1022–1031.
162. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. *Vaccine* 22:2993–3003.
163. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. *Vaccine* 29:5145–5152.
164. Braciale TJ. 1977. Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. *Cell. Immunol.* 33:423–436.
165. Braciale TJ. 1977. Immunologic recognition of influenza virus-infected cells. II. Expression of influenza A matrix protein on the infected cell surface and its role in recognition by cross-reactive cytotoxic T cells. *J. Exp. Med.* 146:673–689.
166. McMichael AJ, Gotch FM, Noble GR, Beare PA. 1983. Cytotoxic T-cell immunity to influenza. *N. Engl. J. Med.* 309:13–17.
167. Topham DJ, Tripp RA, Doherty PC. 1997. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. *J. Immunol.* 159:5197–5200.
168. Shedlock DJ, Shen H. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* 300:337–339.
169. Sun JC, Bevan MJ. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. *Science* 300:339–342.
170. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A. 2008. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. *J. Virol.* 82:12241–12251.
171. Lee LY, Ha DLA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, Townsend AR, Askonas BA, Rowland-Jones S, Dong T. 2008. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. *J. Clin. Invest.* 118:3478–3490.
172. Chen W, McCluskey J. 2006. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. *Adv. Cancer Res.* 95:203–247.
173. Yewdell JW, Bennink JR. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. *Annu. Rev. Immunol.* 17:51–88.
174. La Gruta NL, Turner SJ, Doherty PC. 2004. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. *J. Immunol.* 172:5553–5560.
175. Chen W, Masterman KA, Basta S, Haeryfar SM, Dimopoulos N, Knowles B, Bennink JR, Yewdell JW. 2004. Cross-priming of CD8+ T



- cells by viral and tumor antigens is a robust phenomenon. *Eur. J. Immunol.* 34:194–199.
176. Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B. 1984. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. *Nature* 311:578–579.
  177. Berglund P, Fleeton MN, Smerdou C, Liljestrom P. 1999. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. *Vaccine* 17:497–507.
  178. Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C, Neuhaus D, Zurbriggen R. 2007. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. *Vaccine* 25:7065–7074.
  179. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. 2001. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. *Cell. Immunol.* 211:143–153.
  180. Eliasson DG, Helgeby A, Schon K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lovgren KB, Nystrom I, Lycke NY. 2011. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. *Vaccine* 29:3951–3961.
  181. Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W. 2012. Synthetic influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial. *Vaccine* 30:4655–4660.
  182. Suzuki Y, Nei M. 2002. Origin and evolution of influenza virus hemagglutinin genes. *Mol. Biol. Evol.* 19:501–509.
  183. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD. 2005. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. *J. Virol.* 79:2814–2822.
  184. Air GM. 1981. Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. *Proc. Natl. Acad. Sci. U. S. A.* 78:7639–7643.
  185. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. *Nat. Struct. Mol. Biol.* 16:265–273.
  186. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. *PLoS One* 3:e3942. doi:10.1371/journal.pone.0003942.
  187. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. *Proc. Natl. Acad. Sci. U. S. A.* 105:5986–5991.
  188. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. *Science* 333:843–850.
  189. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. *Science* 333:850–856.
  190. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. 2011. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. *Clin. Infect. Dis.* 52:1003–1009.
  191. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y. 2011. Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. *J. Virol.* 85:11048–11057.
  192. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J. Exp. Med.* 208:181–193.
  193. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. *PLoS Pathog.* 6:e1000796. doi:10.1371/journal.ppat.1000796.
  194. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. *mBio* 1(1):e00018–10. doi:10.1128/mBio.00018-10.
  195. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najjar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R. 2010. Design of an HA2-based *Escherichia coli* expressed influenza immunogen that protects mice from pathogenic challenge. *Proc. Natl. Acad. Sci. U. S. A.* 107:13701–13706.
  196. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. *Proc. Natl. Acad. Sci. U. S. A.* 107:18979–18984.
  197. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA. 2012. Cross-neutralization of influenza A viruses mediated by a single antibody loop. *Nature* 489:526–532.

**Richard J. Webby** is a faculty member of the Department of Infectious Diseases at St. Jude Children's Research Hospital, Memphis, TN. He directs the U.S. National Institutes of Health/NIAID-funded St. Jude Center of Excellence for Influenza Research and Surveillance and also the World Health Organization Collaborating Center for Studies on the Ecology of Influenza in Lower Animals and Birds. Through the latter role, he is involved in the selection and preparation of vaccine reference viruses for influenza viruses of zoonotic potential.



**Sook-San Wong** is currently a Postdoctoral Research Fellow in the laboratory of Dr. Richard Webby in the Department of Infectious Diseases at St. Jude Children's Research Hospital, Memphis, TN. She received her Master's of Medical Sciences from Universiti Malaya, Malaysia, and her Ph.D. from the University of Melbourne, Australia, for her studies on dengue virus. Her research interest is in understanding the interplay at the virus-host interface, particularly within the context of host immunity.

